No 'Unicorn' High-Cost/High-Volume Drugs Expected For 2017
This article was originally published in The Pink Sheet Daily
Executive Summary
Specialty drugs, which have been a key driver of health care spending growth in years past, are not expected to have the same impact in 2017 – mostly because there's no "unicorn" high-cost, high-volume blockbusters anticipated to enter the market next year.